Sonnet Biotherapeutics Holdings Inc expected to post a loss of $1.10 a share - Earnings Preview

Sonnet Biotherapeutics Holdings

03/02/2023 11:51

* Sonnet Biotherapeutics Holdings Inc  SONN.OQ   SONN.O  is
expected to report  results on February 6 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Sonnet
Biotherapeutics
Holdings Inc is for a loss of $1.10 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $22​, above​ its last closing
price of $1.09. ​​​

This summary was machine generated February 3 at 11:51 GMT.  All
figures in US dollars  unless otherwise stated